Neulasta | eHealth News

The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.

FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

HealthDay.com - Jun 5, 2018

Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment

Archives